Biotech Industry Moves Towards a Patent Cliff

Episode Summary

Executive Summary: Antonio Yervolino of Evaluate Pharma says pharma/biotech remains attractive but faces mounting uncertainty from pricing pressure, biosimilars, and tougher market access. He argues growth will continue, driven by innovation, while the industry shifts toward narrower patient populations, biomarker-led development, value-based contracts, and portfolio diversification as big biologics approach a “second patent cliff.”

Main Topics: Industry uncertainty and pricing pressure: Yervolino says uncertainty is inherent in pharma, but U.S. reform, pricing scrutiny, and payer pressure have intensified. He notes brokers and markets are increasingly factoring in affordability concerns. Biosimilars and the second patent cliff: The report highlights a new wave of biosimilar competition against major biologics, which is starting to affect forecasts and could reshape revenue expectations over the next five to six years. Innovation as the core growth engine: Despite headwinds, growth is still expected to come from innovation across oncology, immunology, MS, and cardiovascular disease, with targeted therapies leading the way. Shift from volume to value: Companies are adapting clinical development and pricing strategies to prove incremental benefit versus active comparators and to pursue value-based or cost-sharing reimbursement deals. Orphan drugs and narrowing indications: Orphan and niche indications remain attractive, but their pricing is increasingly under scrutiny as companies pursue smaller, well-defined populations that satisfy payer demands. R&D productivity and the cost of development: The interview stresses that drug development remains expensive and inefficient, with clinical attrition high and multi-indication development increasing the burden on R&D budgets. M&A and portfolio diversification: Yervolino sees liquidity, tax reform, and patent expirations as possible catalysts for M&A, but thinks bolt-on acquisitions and internal R&D will remain the dominant strategies.

Key Arguments: Pharma uncertainty is permanent because it is rooted in both clinical development risk and pricing/reimbursement risk. Evaluate Pharma still forecasts 6.5% year-on-year industry growth, even while revising its outlook downward for the first time in 10 years. Pricing pressure is driven by the high cost of new therapies and by payer resistance, especially in the U.S. where PBMs have become a major hurdle. Biosimilars are becoming a real commercial force, and credibility is improving as major biotech firms rather than only generics companies enter the market. Innovation remains the main growth driver, particularly in oncology, immunology, MS, and even historically slower areas like cardiovascular disease. Orphan drug strategies are proliferating, but their pricing is increasingly exposed because companies are targeting narrower patient groups. Companies are moving from placebo-controlled development toward active comparators and biomarker-defined populations to demonstrate value. R&D productivity remains a challenge; high attrition and the need to support multiple indications make development more costly. AI and related tools may improve early discovery efficiency, but they do not substantially reduce the complexity or cost of clinical development. M&A could accelerate if tax repatriation or liquidity unlocks capital, but historical bolt-on deals may be more value-creating than large transformative mergers.

Data Points: Forecast industry growth: 6.5% year-on-year - Evaluate Pharma expects continued positive growth despite uncertainty. Forecast revision: First downward revision in 10 years - The outlook was lowered for the first time in a decade due to pricing and biosimilar pressures. Biosimilar horizon: 5 to 6 years - Brokers increasingly see the biosimilars market becoming reality within this timeframe. Development cost per approval: $4 billion - Cited as the cost to get a new molecular entity approved, illustrating R&D inefficiency. Pipeline expansion: 15 planned indications - Used to describe how products like Keytruda and Opdivo now require multiple follow-on indication programs. Timeframe for first patent cliff: 5 to 10 years ago - Describes the earlier wave of patent expirations affecting small molecules. Interview context: Bio 2017 International Convention in San Diego - The conversation was recorded live, with crowd noise in the background.

Pivotal Quotes: "Uncertainty will never fade away." — Antonio Yervolino: He is explaining that risk is inherent in pharma because of clinical failure risk and pricing uncertainty. "For the first time in 10 years, our focus has been revised downward." — Antonio Yervolino: He is referring to Evaluate Pharma’s lowered outlook due to pricing and biosimilar competition. "We tend to call it the second patent cliff era." — Antonio Yervolino: He is describing the coming wave of biologics losing protection to biosimilars.

Implications: The sector still offers growth, but success will depend on proving value, targeting defined patients, and planning for biosimilar erosion. Companies that combine strong R&D with smarter pricing, evidence generation, and portfolio diversification will be best positioned.